Do you want to read an article? Please log in or register.
Comparison of gefitinib, erlotinib and afatinib in non-small cell lung cancer: A meta-analysis
Gastrointestinal CancerLung, Respiratory and Thoracic Cancer
Related content
Lung, Respiratory and Thoracic Cancer
Cost-Effectiveness Analysis of Afatinib versus Gefitinib for First-Line Treatment of Advanced EGFR-Mutated Advanced Non-Small Cell Lung Cancers
J Thorac Oncol.
Chouaid C, Luciani L, LeLay K, Do P, Bennouna J, Perol M, Moro-Sibilot D, Vergnenègre A, de Pouvourville G
doi: 10.1016/j.jtho.2017.07.013.
Lung, Respiratory and Thoracic Cancer
Low-Dose Erlotinib Treatment in Elderly or Frail Patients With EGFR Mutation-Positive Non-Small Cell Lung Cancer: A Multicenter Phase 2 Trial
JAMA Oncol.
Miyamoto S, Azuma K, Ishii H, Bessho A, Hosokawa S, Fukamatsu N, Kunitoh H, Ishii M, Tanaka H, Aono H, Nakahara Y, Kusaka K, Hosomi Y, Kikuchi N, Mori Y, Itani H, Hamada A, Yamada K, Okamoto H
doi: 10.1001/jamaoncol.2020.1250.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Non-interventional LUME-BioNIS study of nintedanib plus docetaxel after chemotherapy in adenocarcinoma non-small cell lung cancer: A subgroup analysis in patients with prior immunotherapy
★ 1
Recommended by
Dr Wolf-Dieter Janthur, Faculty Member
Lung Cancer.
Reck M, Syrigos K, Miliauskas S, Zöchbauer-Müller S, Fischer JR, Buchner H, Kitzing T, Kaiser R, Radonjic D, Kerr K
doi: 10.1016/j.lungcan.2020.08.004.
Lung, Respiratory and Thoracic Cancer
Successful treatment with afatinib after grade 3 hepatotoxicity induced by both gefitinib and erlotinib in EGFR mutation-positive non-small cell lung cancer
Lung Cancer.
Zenke Y, Umemura S, Sugiyama E, Kirita K, Matsumoto S, Yoh K, Niho S, Ohmatsu H, Goto K.
doi: 10.1016/
Lung Cancer
Molecular Diagnostic and Precision Medicine in Non-Small Cell Lung Cancer. An Update on the Treatment of the Most Important Actionable Oncogenic Driver Alterations.
1Department of Medical Oncology, University Hospital Basel, Basel, Switzerland.
RECOMMENDED
Lung, Respiratory and Thoracic Cancer
Randomized Trial of Afatinib Plus Cetuximab Versus Afatinib Alone for First-Line Treatment of EGFR-Mutant Non-Small-Cell Lung Cancer: Final Results From SWOG S1403
★ 1
Recommended by
Alexander Meisel, Faculty Member
J Clin Oncol.
Goldberg SB, Redman MW, Lilenbaum R, Politi K, Stinchcombe TE, Horn L, Chen EH, Mashru SH, Gettinger SN, Melnick MA, Herbst RS, Baumgart MA, Miao J, Moon J, Kelly K, Gandara DR
doi: 10.1200/JCO.20.01149.Visit the original publication at ncbi.nlm.nih.gov
Lung, Respiratory and Thoracic Cancer
RNA-based analysis of ALK fusions in non-small cell lung cancer cases showing IHC/FISH discordance
doi: 10.1186/s12885-018-5070-6.
Lung, Respiratory and Thoracic Cancer
Efficacy and safety of ALK inhibitors in ALK-rearranged non-small cell lung cancer: A systematic review and meta-analysis
Lung Cancer.
Breadner D, Blanchette P, Shanmuganathan S, Boldt RG, Raphael J
doi: 10.1016/j.lungcan.
Lung, Respiratory and Thoracic Cancer
Comparison of early tumour-associated versus late deaths in patients with central or >7 cm T4 N0/1 M0 non-small-cell lung-cancer undergoing trimodal treatment: Only few risks left to improve
Eur J Cancer.
Guberina N, Pöttgen C, Schuler M, Guberina M, Stamatis G, Plönes T, Krebs B, Metzenmacher M, Theegarten D, Gauler T, Jöckel KH, Darwiche K, Aigner C, Stuschke M, Eberhardt WE
doi: 10.1016/j.ejca.2020.07.025.